Company / SG&A Expense
Solventum SG&A Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$3.1B
FY2025
5-year range
$2.2B / $3.1B
FY2022-FY2025
Trend
+10.7%
vs FY2024
Sector context
#20 of 158
Health Care
What the data says
Solventum's sg&a expense of $3.1B is higher than 87% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $2.2B in FY2022 to $3.1B in FY2025.
Based on SEC 10-K filings.
$3.1B in FY2025 with a 3-year CAGR of +11.3%. Top quartile in the Health Care sector.
Increased from $2.3B to $3.1B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 158This company $3.1B Sector average $175.9B
▼
-98.2% below sector average
Key checks
Key Insights
- Solventum's sg&a expense has grown for 3 consecutive years.
- 3-year CAGR of +11.3%, indicating consistent growth.
- In FY2025, sg&a expense increased 10.7% year-over-year.
- Ranks #20 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 30.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.1B | +10.7% |
| FY2024 | $2.8B | +21.0% |
| FY2023 | $2.3B | +2.9% |
| FY2022 | $2.2B | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026